GlassScriptPhysician profile
Katherine Joy Hendricks
NPI 1700404019
$2,583.48
in general payments reported to CMS, 2019-2025
15 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $533 · 2022: $878 · 2023: $482 · 2024: $399 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $891.04 | 2021-2025 | Relistor |
| Forte Bio-Pharma LLC | $786.60 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Grt US Holding, INC. | $254.17 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $173.89 | 2022-2023 | Belbuca |
| Nevro Corp. | $113.86 | 2021-2024 | Senza |
| Scilex Pharmaceuticals INC. | $90.02 | 2021-2023 | Ztlido |
| Uswm, LLC | $79.80 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $63.00 | 2022 | |
| Redhill Biopharma INC. | $26.13 | 2021 | |
| Amgen INC. | $25.82 | 2022 | |
| Protega Pharmaceutials INC | $20.88 | 2023 | Roxybond |
| Virtus Pharmaceuticals LLC | $15.80 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.23 | 2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $15.19 | 2025 | |
| Boston Scientific Corporation | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Hendricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.